Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02938520
Registration number
NCT02938520
Ethics application status
Date submitted
15/09/2016
Date registered
19/10/2016
Date last updated
31/08/2023
Titles & IDs
Public title
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
Query!
Scientific title
A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants
Query!
Secondary ID [1]
0
0
2016-001646-25
Query!
Secondary ID [2]
0
0
201584
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HIV Infections
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Acquired immune deficiency syndrome (AIDS / HIV)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cabotegravir (CAB) tablet
Treatment: Drugs - Rilpivirine (RPV) tablet
Treatment: Drugs - Cabotegravir - Injectable Suspension (CAB LA)
Treatment: Drugs - Rilpivirine - Injectable Suspension (RPV LA)
Treatment: Drugs - ABC/DTG/3TC STR - Tablet
Treatment: Drugs - DTG Tablet
Experimental: CAB LA + RPV LA every 4 weeks - After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks.
Active Comparator: ABC / DTG / 3TC (600 mg/50mg/300mg) once daily - After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing at either Week 100 (direct to inject) or Week 104b (if using optional oral lead-in with CAB 30 mg + RPV 25 mg once daily).
Treatment: Drugs: Cabotegravir (CAB) tablet
It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
Treatment: Drugs: Rilpivirine (RPV) tablet
It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with "TMC" and the other side with "25". Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose.
Treatment: Drugs: Cabotegravir - Injectable Suspension (CAB LA)
It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
Treatment: Drugs: Rilpivirine - Injectable Suspension (RPV LA)
It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Treatment: Drugs: ABC/DTG/3TC STR - Tablet
It is a purple, biconvex, oval, tablet debossed with "572 Tri" on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.
Treatment: Drugs: DTG Tablet
It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with "SV 572" on one side and "50" on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48
Query!
Assessment method [1]
0
0
Percentage of participants with virologic failure endpoint (HIV-1 RNA>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the noninferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC regimen over 48 weeks in HIV-1 infected ARTexperienced participants. The HIV-1 RNA >=50 copies/mL per snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks) or at time of discontinuation (if discontinuation occurred prior to Week 48 for reasons other than Adverse Event).
Query!
Timepoint [1]
0
0
Week 48
Query!
Secondary outcome [1]
0
0
Percentage of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48
Query!
Assessment method [1]
0
0
Percentage of participants with plasma HIV-1 RNA <50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC. The HIV-1 RNA <50 copies/mL per snapshot algorithm was determined by last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks). Participants with no data in the analysis window were classificated as non-responders.
Query!
Timepoint [1]
0
0
Week 48
Query!
Secondary outcome [2]
0
0
Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48
Query!
Assessment method [2]
0
0
Percentage of participants with plasma HIV-1 RNA <200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC
Query!
Timepoint [2]
0
0
Week 48
Query!
Secondary outcome [3]
0
0
Number of Participants With Confirmed Virologic Failure (CVF) During the Maintenance Phase
Query!
Assessment method [3]
0
0
The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels >=200 copies/mL after prior suppression to <200 copies/mL.
Query!
Timepoint [3]
0
0
Week 48
Query!
Secondary outcome [4]
0
0
Absolute Values for Plasma HIV-1 RNA at Week 48
Query!
Assessment method [4]
0
0
Plasma for quantitative HIV-1 RNA were collected at indicated time points. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.
Query!
Timepoint [4]
0
0
Week 48
Query!
Secondary outcome [5]
0
0
Change From Baseline Values for Plasma HIV-1 RNA at Week 48
Query!
Assessment method [5]
0
0
Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 minus HIV-1 RNA(log 10) at Baseline.
Query!
Timepoint [5]
0
0
Baseline (Day 1) and at Week 48
Query!
Secondary outcome [6]
0
0
Absolute Values for CD4+ Lymphocyte Count at Week 48
Query!
Assessment method [6]
0
0
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC
Query!
Timepoint [6]
0
0
Week 48
Query!
Secondary outcome [7]
0
0
Change From Baseline Values for CD4+ Lymphocyte Count at Week 48
Query!
Assessment method [7]
0
0
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value at Week 48 minus Maintenance Baseline value.
Query!
Timepoint [7]
0
0
Baseline (Day 1) and Week 48
Query!
Secondary outcome [8]
0
0
Number of Participants With Disease Progression
Query!
Assessment method [8]
0
0
Data for participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented. CDC stage is derived according to lowest post baseline CD4+ T-lympohocyte count and/or occurrence of AIDS-defining conditons (per 2014 CDC criteria).
Query!
Timepoint [8]
0
0
Day 1 up to an average of 59 weeks
Query!
Secondary outcome [9]
0
0
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [9]
0
0
An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment. Safety Population: all randomized participants who received at least 1 dose of IP during maintenance phase and assessed according to actual treatment received. All Maintenance Phase AEs was presented including AEs with start date occurring on/after date of 1st dose of randomized treatment, up to and including start date of LTFU antiretroviral therapy for participants who discontinued from Q4W arm. Non-SAE counts in >=5% of participants within any arm is reported
Query!
Timepoint [9]
0
0
Day 1 up to an average of 59 Weeks
Query!
Secondary outcome [10]
0
0
Number of Participants With Severity of Adverse Events
Query!
Assessment method [10]
0
0
Severity of adverse events (AEs) were defined as per The Division of acquired immuno deficiency syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE. All Maintenance Phase adverse events have been presented, which includes AEs with start date occuring on or after the date of first dose of randomized study treatment, up to and including the start date of LTFU antiretroviral therapy for participants who discontinued from the Q4W arm.
Query!
Timepoint [10]
0
0
Up to Week 48
Query!
Secondary outcome [11]
0
0
Absolute Values for Hematology Parameters Over Time Including Week 48: Basophils, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
Query!
Assessment method [11]
0
0
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.
Query!
Timepoint [11]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [12]
0
0
Absolute Values for Hematology Parameters Over Time Including Week 48: Erythrocyte Mean Corpuscular Volume
Query!
Assessment method [12]
0
0
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints.
Query!
Timepoint [12]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [13]
0
0
Absolute Values for Hematology Parameters Over Time Including Week 48: Erythrocytes
Query!
Assessment method [13]
0
0
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints.
Query!
Timepoint [13]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [14]
0
0
Absolute Values for Hematology Parameters Over Time Including Week 48: Hemoglobin
Query!
Assessment method [14]
0
0
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints.
Query!
Timepoint [14]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [15]
0
0
Absolute Values for Hematology Parameters Over Time Including Week 48: Hematocrit
Query!
Assessment method [15]
0
0
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints.
Query!
Timepoint [15]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [16]
0
0
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)
Query!
Assessment method [16]
0
0
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated timepoints.
Query!
Timepoint [16]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [17]
0
0
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Query!
Assessment method [17]
0
0
Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated timepoints.
Query!
Timepoint [17]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [18]
0
0
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Query!
Assessment method [18]
0
0
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated timepoints.
Query!
Timepoint [18]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [19]
0
0
Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48
Query!
Assessment method [19]
0
0
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated timepoints.
Query!
Timepoint [19]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [20]
0
0
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Query!
Assessment method [20]
0
0
Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated timepoints.
Query!
Timepoint [20]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [21]
0
0
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.
Query!
Assessment method [21]
0
0
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
Query!
Timepoint [21]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [22]
0
0
Absolute Values for Fasting Lipid Panel Overtime Including Week 48
Query!
Assessment method [22]
0
0
Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.
Query!
Timepoint [22]
0
0
Baseline (Day 1) and at Week 48
Query!
Secondary outcome [23]
0
0
Number of Participants With Abnormal Urinalysis Parameter Over Time Including Week 48
Query!
Assessment method [23]
0
0
The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to DAIDS scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.
Query!
Timepoint [23]
0
0
Baseline (Day 1) and at Weeks 4, 24 and 48
Query!
Secondary outcome [24]
0
0
Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48
Query!
Assessment method [24]
0
0
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).
Query!
Timepoint [24]
0
0
Baseline (Day 1) and at Weeks 4, 24 and 48
Query!
Secondary outcome [25]
0
0
Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
Query!
Assessment method [25]
0
0
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
Query!
Timepoint [25]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [26]
0
0
Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume
Query!
Assessment method [26]
0
0
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
Query!
Timepoint [26]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [27]
0
0
Change From Baseline for Hematology Parameters: Erythrocytes
Query!
Assessment method [27]
0
0
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
Query!
Timepoint [27]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [28]
0
0
Change From Baseline for Hematology Parameters: Hematocrit
Query!
Assessment method [28]
0
0
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.
Query!
Timepoint [28]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [29]
0
0
Change From Baseline for Hematology Parameters: Hemoglobin
Query!
Assessment method [29]
0
0
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Query!
Timepoint [29]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [30]
0
0
Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK
Query!
Assessment method [30]
0
0
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [30]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [31]
0
0
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Query!
Assessment method [31]
0
0
Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [31]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [32]
0
0
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Query!
Assessment method [32]
0
0
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [32]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [33]
0
0
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48
Query!
Assessment method [33]
0
0
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [33]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [34]
0
0
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Query!
Assessment method [34]
0
0
Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [34]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [35]
0
0
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance
Query!
Assessment method [35]
0
0
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [35]
0
0
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [36]
0
0
Change From Baseline Values for Fasting Lipid Panel and Glucose Overtime Including Week 48
Query!
Assessment method [36]
0
0
Blood samples were collected at Baseline and at Week 48 to assess glucose and fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. Only fasting data is presented for glucose and lipids. Baseline value is defined as the last available fasting recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at Week 48 visit (if collected while fasting) minus the Baseline value.
Query!
Timepoint [36]
0
0
Baseline (Day 1) and at Week 48
Query!
Secondary outcome [37]
0
0
Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48
Query!
Assessment method [37]
0
0
Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [37]
0
0
Baseline (Day 1) and at Weeks 4, 24 and 48
Query!
Secondary outcome [38]
0
0
Change From Baseline Values in Urine Creatinine Over Time Including Week 48
Query!
Assessment method [38]
0
0
Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [38]
0
0
Baseline (Day 1) and at Weeks 4, 24 and 48
Query!
Secondary outcome [39]
0
0
Change From Baseline Values in Urine Phosphate Over Time Including Week 48
Query!
Assessment method [39]
0
0
Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [39]
0
0
Baseline (Day 1) and at Weeks 4, 24 and 48
Query!
Secondary outcome [40]
0
0
Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48
Query!
Assessment method [40]
0
0
Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [40]
0
0
Baseline (Day 1) and at Week 48
Query!
Secondary outcome [41]
0
0
Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48
Query!
Assessment method [41]
0
0
Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.
Query!
Timepoint [41]
0
0
Baseline (Day 1) and at Weeks 4, 24 and 48
Query!
Secondary outcome [42]
0
0
Change From Baseline Values in Urine pH Over Time Including Week 48
Query!
Assessment method [42]
0
0
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [42]
0
0
Baseline (Day 1) and at Weeks 4, 24 and 48
Query!
Secondary outcome [43]
0
0
Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48
Query!
Assessment method [43]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. All Maintenance Phase adverse events (start date occurring on or after the date of first dose of randomized study treatment) leading to withdrawal have been presented.
Query!
Timepoint [43]
0
0
Up to Week 48
Query!
Secondary outcome [44]
0
0
Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48
Query!
Assessment method [44]
0
0
Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the last available recorded fasting value up to and including the date of first Maintenance Phase dose of IP. Percentage change from baseline is calculated as: value at Week 48 (if collected while fasting) minus Baseline value divided by Baseline value multiplied by 100.
Query!
Timepoint [44]
0
0
Baseline (Day 1) and at Week 48
Query!
Secondary outcome [45]
0
0
Number of Participants With Phenotypic Resistance Through Week 48
Query!
Assessment method [45]
0
0
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Phenotypic Resistance data for following drugs :CAB,dolutegravir(DTG),elvitegravir (EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI),atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),ritonavir(RTV), saquinavir(SQV) and tipranavir (TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance (FC>clinical higher cutoff/biologic cutoff),partially sensitive (FC=clinical higher cutoff and > clinical lower cutoff),sensitive(FC<=clinical lower cutoff/biologic cutoff). The CVF population comprised of all participants in ITT-E population who met CVF criteria
Query!
Timepoint [45]
0
0
Week 48
Query!
Secondary outcome [46]
0
0
Number of Participants With Genotypic Resistance Through Week 48
Query!
Assessment method [46]
0
0
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.
Query!
Timepoint [46]
0
0
Week 48
Query!
Secondary outcome [47]
0
0
Area Under the Curve (AUC) for CAB LA
Query!
Assessment method [47]
0
0
AUC values are Bayesian pharmacokinetic (PK) parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for CAB LA. The PK Population includes all participants who received CAB and / or RPV and undergo PK sampling during the study, and provide CAB and /or RPV plasma concentration data.
Query!
Timepoint [47]
0
0
Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5, 41, 2 hours post-dose at Weeks 4 and 48
Query!
Secondary outcome [48]
0
0
AUC for RPV LA
Query!
Assessment method [48]
0
0
AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for RPV LA
Query!
Timepoint [48]
0
0
Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5, 41, 2 hours post-dose at Weeks 4 and 48
Query!
Secondary outcome [49]
0
0
Plasma Trough Concentration (Ctrough) for CAB LA Evaluable
Query!
Assessment method [49]
0
0
Blood samples were collected at indicated time points for PK analysis of CAB LA.
Query!
Timepoint [49]
0
0
Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [50]
0
0
Ctrough for RPV LA Evaluable
Query!
Assessment method [50]
0
0
Blood samples were collected at indicated time points for PK analysis of RPV LA.
Query!
Timepoint [50]
0
0
Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Query!
Secondary outcome [51]
0
0
Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41
Query!
Assessment method [51]
0
0
Blood samples will be collected at indicated time points for PK analysis of CAB LA.
Query!
Timepoint [51]
0
0
Week 41- 1 Week post dose
Query!
Secondary outcome [52]
0
0
Cmax in Plasma for RPV LA Evaluable at Week 41
Query!
Assessment method [52]
0
0
Blood samples will be collected at indicated time points for PK analysis of RPV LA.
Query!
Timepoint [52]
0
0
Week 41- 1 Week post dose
Query!
Secondary outcome [53]
0
0
Change From Week 5 in Dimension Scores Using Perception of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF)
Query!
Assessment method [53]
0
0
PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis
Query!
Timepoint [53]
0
0
Weeks 5 and at Weeks 41 and 48
Query!
Secondary outcome [54]
0
0
Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire
Query!
Assessment method [54]
0
0
PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment, following visit and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis.
Query!
Timepoint [54]
0
0
Weeks 5, 41 and 48
Query!
Secondary outcome [55]
0
0
Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire
Query!
Assessment method [55]
0
0
The HATQoL questionnaire was used to assess health related QoL (HRQoL). It comprises of three dimensions: life satisfaction (LISAT), medication worries (MEDWO) and disclosure worries (DISWO). For LISAT domain, each question is scored as 1-5, where 5 corresponds to satisfaction 'all of time' and 1 as 'none of time'. Total score for the LISAT domain (sum of item scores for questions 1a to 1d) is transformed to a 0-100 scale using formula:[100 divided by (20 minus 4)]*(raw total score for LISAT minus 4). Higher the LISAT score, greater satisfaction to life. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Query!
Timepoint [55]
0
0
Baseline (Day 1) and at Weeks 24 and 48
Query!
Secondary outcome [56]
0
0
Change From Baseline in HIV Medication, MEDWO Using HATQoL
Query!
Assessment method [56]
0
0
The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the MEDWO domain, each question is scored as 1-5, where 5 is associated with medication worry 'none of the time' and 1 as 'all of the time'. The total score for the MEDWO domain (sum of item scores for questions 2a to 3e) is transformed to a 0-100 scale using formula: [100 divided by (25 minus 5)]* (raw total score for MEDWO minus 5). Higher MEDWO scores correspond to lower medication worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Query!
Timepoint [56]
0
0
Baseline and at Weeks 24 and 48
Query!
Secondary outcome [57]
0
0
Change From Baseline in DISWO Using HATQoL
Query!
Assessment method [57]
0
0
The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the DISWO domain, each question is scored as 1-5, where 5 is associated with disclosure worry 'none of the time' and 1 as 'all of the time'. The total score for the DISWO domain (sum of item scores for questions 3a to 3e) is transformed to a 0-100 scale using formula: [100 divided by (25 minus 5)]* (raw total score for DISWO minus 5). Higher DISWO total scores correspond to lower disclosure worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Query!
Timepoint [57]
0
0
Baseline and at Weeks 24 and 48
Query!
Secondary outcome [58]
0
0
Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12)
Query!
Assessment method [58]
0
0
The SF-12 questionnaire consists of 7 questions which measures degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. HRQoL using SF-12 for physical component summary (PCS) and mental component summary (MCS) were assessed for two treatment groups.Missing component scores was imputed using LOCF.PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com).The higher the score, the better will be the health status.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Query!
Timepoint [58]
0
0
Baseline and at Weeks 24 and 48
Query!
Secondary outcome [59]
0
0
Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44
Query!
Assessment method [59]
0
0
HIVTSQs (status version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range of 0 to 66. Higher the score, greater improvement in satisfaction with treatment; lower score, greater the deterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value. Adjusted mean and 95% CI of adjusted mean values has been presented.
Query!
Timepoint [59]
0
0
Baseline and at Weeks 4b, 24 and 44
Query!
Secondary outcome [60]
0
0
Change in Treatment Satisfaction Over Time Using HIVTSQc at Week 48
Query!
Assessment method [60]
0
0
HIVTSQc (change version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range:-33 to 33. Higher scores represent greater improvement in treatment satisfaction compared to satisfaction with treatment received during the induction phase; lower scores representedeterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Query!
Timepoint [60]
0
0
Week 48
Query!
Secondary outcome [61]
0
0
Change From Baseline in Individual Item Scores of HIVTSQs at Weeks 4b, 24 and 44
Query!
Assessment method [61]
0
0
HIVTSQs (status version) is a 12 item questionnaire. The individual item scores are ratedas 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater treatment satisfaction as compared to the past few weeks. LOCF was used as primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Query!
Timepoint [61]
0
0
Baseline and at Weeks 4b, 24 and 44
Query!
Secondary outcome [62]
0
0
Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using "General Acceptance" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire
Query!
Assessment method [62]
0
0
ACCEPT questionnaire is generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication. It consists 25 items, capturing six dimensions. 3 questions focusing on general acceptance of study medication were analyzed. Items scores are rated as 1-5 :1-totally disagree,2-somewhat disagree,3-somewhat agree,4-totally agree and 5-I don't know. The acceptance domain score (ranging from 0 to 100) is calculated using the following formula:100*(mean of recoded items in dimension minus 1) divided by 2.LOCF was primary method of analysis. Measure type is mean for adjusted mean and dispersion measure: 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.
Query!
Timepoint [62]
0
0
Baseline and at Weeks 8, 24 and 48
Query!
Secondary outcome [63]
0
0
Change From 4b in Tolerability of Injection at Weeks 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm
Query!
Assessment method [63]
0
0
The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.
Query!
Timepoint [63]
0
0
Weeks 4b, 5, 40 and 41
Query!
Eligibility
Key inclusion criteria
- HIV-1 infected, ART-naive men or women aged 18 years or greater at
the time of signing the informed consent. - HIV-1 infection as documented by Screening
plasma HIV-1 RNA >=1000 c/mL; - Antiretroviral-naive (<=10 days of prior therapy with any
antiretroviral agent following a diagnosis of HIV-1 infection). Any previous exposure to an
HIV integrase inhibitor or non-nucleoside reverse transcriptase inhibitor will be
exclusionary. - Female Participants: A female participant is eligible to participate if she
is not pregnant at Screening and first day of Induction Phase (as confirmed by a negative
serum human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the
following conditions applies: Non-reproductive potential defined as: Pre-menopausal females
with one of the following: Documented tubal ligation; Documented hysteroscopic tubal
occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy;
Documented Bilateral Oophorectomy; Postmenopausal defined as 12 months of spontaneous
amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating
hormone (FSH) and estradiol levels consistent with menopause. Females on hormone
replacement therapy (HRT) and whose menopausal status is in doubt will be required to use
one of the highly effective contraception methods if they wish to continue their HRT during
the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal
status prior to study enrolment. Reproductive potential and agrees to follow one of the
options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in
Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study
medication, throughout the study, and for at least 30 days after discontinuation of all
oral study medications and for at least 52 weeks after discontinuation of CAB LA and RPV
LA. The investigator is responsible for ensuring that participants understand how to
properly use these methods of contraception. All participants in the study should be
counseled on safer sexual practices including the use and benefit/risk of effective barrier
methods (e.g., male condom) and on the risk of HIV transmission to an uninfected partner. -
Capable of giving signed informed consent which includes compliance with the requirements
and restrictions listed in the consent form and in this protocol. - In France, a
participant will be eligible for inclusion in this study only if either affiliated to or a
beneficiary of a social security category.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Women who are pregnant, breastfeeding, or plan to become pregnant or
breastfeed during the study. - Any evidence at Screening of an active Centers for Disease
and Prevention Control (CDC) Stage 3 disease, except cutaneous Kaposi's sarcoma not
requiring systemic therapy or historic or current cluster of differentiation4+ (CD4+) cell
count <200 cells/ cubic millimeter (mm^3) are not exclusionary. - Participants with known
moderate to severe hepatic impairment. - Any pre-existing physical or mental condition
(including substance abuse disorder) which, in the opinion of the Investigator, may
interfere with the participant's ability to comply with the dosing schedule and/or protocol
evaluations or which may compromise the safety of the participant. - Participants
determined by the Investigator to have a high risk of seizures, including participants with
an unstable or poorly controlled seizure disorder. A participant with a prior history of
seizure may be considered for enrolment if the Investigator believes the risk of seizure
recurrence is low. All cases of prior seizure history should be discussed with the Medical
Monitor prior to enrolment. - Participant who, in the investigator's judgment, poses a
significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal
ideation should be considered when evaluating for suicide risk. - The participant has a
tattoo or other dermatological condition overlying the gluteus region which may interfere
with interpretation of injection site reactions. - Evidence of Hepatitis B virus (HBV)
infection based on the results of testing at Screening for Hepatitis B surface antigen
(HBsAg), Hepatitis B core antibody (anti HBc), Hepatitis B surface antibody (anti-HBs) and
HBV dioxyribose nucleic acid (DNA) as follows: Participants positive for HBsAg are
excluded; Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg
status) and positive for HBV DNA are excluded. Note: Participants positive for anti-HBc
(negative HBsAg status) and positive for anti-HBs (past and/or current evidence) are immune
to HBV and are not excluded. - Asymptomatic individuals with chronic hepatitis C virus
(HCV) infection will not be excluded, however Investigators must carefully assess if
therapy specific for HCV infection is required; participants who are anticipated to require
HCV treatment prior to Week 48 of the Maintenance Phase must be excluded. HCV treatment on
study may be permitted post Week 48, following consultation with the Medical Monitor.
Participants with HCV co-infection will be allowed entry into Phase 3 studies if: Liver
enzymes meet entry criteria; HCV Disease has undergone appropriate work-up, HCV is not
advanced, and will not require treatment prior to the Week 48 visit. Additional information
(where available) on participants with HCV co-infection at screening should include results
from any liver biopsy, fibroscan, ultrasound, or other fibrosis evaluation, history of
cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV
treatment. In the event that recent biopsy or imaging data is not available or is
inconclusive, the Fib-4 score will be used to verify eligibility. A Fib-4 score > 3.25 is
exclusionary; Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation. Fibrosis 4
Score Formula: (Age x AST)/(Platelets x [square root of ALT]). - Unstable liver disease (as
defined by any of the following: presence of ascites, encephalopathy, coagulopathy,
hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary
abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or
otherwise stable chronic liver disease per investigator assessment). - History of liver
cirrhosis with or without hepatitis viral co-infection. - Ongoing or clinically relevant
pancreatitis. - All participants will be screened for syphilis (rapid plasma reagin [RPR]).
Participants with untreated syphilis infection, defined as a positive RPR without clear
documentation of treatment, are excluded. Participants with a positive RPR test who have
not been treated may be rescreened at least 30 days after completion of antibiotic
treatment for syphilis. - Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal
cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical,
anal or penile intraepithelial neoplasia; other localized malignancies require agreement
between the investigator and the study Medical Monitor for inclusion of the participant
prior to enrollment. - Any condition which, in the opinion of the Investigator, may
interfere with the absorption, distribution, metabolism or excretion of the drug or render
the participant unable to receive study medication. - History or presence of allergy or
intolerance to the study drugs or their components or drugs of their class. In addition, if
heparin is used during pharmacokinetic sampling (PK) sampling, participants with a history
of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled. -
Current or anticipated need for chronic anti-coagulation. - Alanine aminotransferase (ALT)
>=3 times upper limit normal (ULN). - Clinically significant cardiovascular disease, as
defined by history/evidence of congestive heart failure, symptomatic arrhythmia,
angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous
transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease. -
Exposure to an experimental drug and/or experimental vaccine within 28 days or 5 half-lives
of the test agent, or twice the duration of the biological effect of the test agent,
whichever is longer, prior to the first dose of investigational product (IP). - Treatment
with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic
chemotherapeutic agents; tuberculosis (TB) therapy, with the exception of treatment of
latent TB with isoniazid; Immunomodulators that alter immune responses (such as chronic
systemic corticosteroids, interleukins, or interferons). Note: Participants using
short-term (e.g. =<21 day) systemic corticosteroid treatment, topical, inhaled or
intranasal corticosteroids are eligible for enrollment. - Treatment with an HIV-1
immunotherapeutic vaccine within 90 days of Screening. - Treatment with any agent, except
recognized ART as allowed above, with documented activity against HIV-1 within 28 days of
the first dose of IP. - Use of medications which are associated with Torsades de Pointes -
Any evidence of primary resistance to non-nuclease reverse transcriptase inhibitors
(NNRTIs) (except for K103N which is allowed), or any known resistance to INIs from
historical resistance test results. Note: re-tests of Screening genotypes are allowed only
at the discretion of the study virologist. - Participants who are HLA-B*5701 positive and
are unable to use an nuclease reverse transcriptase inhibitors (NRTI) backbone that does
not contain abacavir (participants who are HLA-B*5701 positive may be enrolled if they use
a NRTI backbone that does not contain abacavir; HLA-B*5701 positive participants may be
excluded from the study if local provision of an alternate NRTI backbone is not possible).
- Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the
Screening Phase to verify a result. - Any acute laboratory abnormality at Screening, which,
in the opinion of the Investigator, would preclude the participant's participation in the
study of an investigational compound. - Participant has estimated creatinine clearance <50
mL/min/1.73m^2 via the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation. - Participants who are currently participating in or anticipate to be selected
for any other interventional study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/10/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2026
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
631
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Minnesota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nebraska
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Jersey
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Rhode Island
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Virginia
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
British Columbia
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Ontario
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Quebec
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Bobigny
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Lyon Cedex 03
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Marseille.
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Paris Cedex 10
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Paris Cedex 12
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Paris Cedex 13
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Paris Cedex 20
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Bayern
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Hessen
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Niedersachsen
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Nordrhein-Westfalen
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Berlin
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Hamburg
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
München
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Lazio
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Lombardia
Query!
Country [35]
0
0
Japan
Query!
State/province [35]
0
0
Aichi
Query!
Country [36]
0
0
Japan
Query!
State/province [36]
0
0
Osaka
Query!
Country [37]
0
0
Japan
Query!
State/province [37]
0
0
Tokyo
Query!
Country [38]
0
0
Netherlands
Query!
State/province [38]
0
0
Amsterdam
Query!
Country [39]
0
0
Netherlands
Query!
State/province [39]
0
0
Groningen
Query!
Country [40]
0
0
Netherlands
Query!
State/province [40]
0
0
Rotterdam
Query!
Country [41]
0
0
Netherlands
Query!
State/province [41]
0
0
Utrecht
Query!
Country [42]
0
0
Russian Federation
Query!
State/province [42]
0
0
Ekaterinburg
Query!
Country [43]
0
0
Russian Federation
Query!
State/province [43]
0
0
Kazan
Query!
Country [44]
0
0
Russian Federation
Query!
State/province [44]
0
0
Kemerovo
Query!
Country [45]
0
0
Russian Federation
Query!
State/province [45]
0
0
Krasnodar
Query!
Country [46]
0
0
Russian Federation
Query!
State/province [46]
0
0
Lipetsk
Query!
Country [47]
0
0
Russian Federation
Query!
State/province [47]
0
0
Moscow
Query!
Country [48]
0
0
Russian Federation
Query!
State/province [48]
0
0
Orel
Query!
Country [49]
0
0
Russian Federation
Query!
State/province [49]
0
0
Saint-Petersburg
Query!
Country [50]
0
0
Russian Federation
Query!
State/province [50]
0
0
Saratov
Query!
Country [51]
0
0
Russian Federation
Query!
State/province [51]
0
0
Smolensk
Query!
Country [52]
0
0
Russian Federation
Query!
State/province [52]
0
0
St. Petersburg
Query!
Country [53]
0
0
Russian Federation
Query!
State/province [53]
0
0
Toliyatti
Query!
Country [54]
0
0
South Africa
Query!
State/province [54]
0
0
Free State
Query!
Country [55]
0
0
South Africa
Query!
State/province [55]
0
0
Gauteng
Query!
Country [56]
0
0
South Africa
Query!
State/province [56]
0
0
KwaZulu- Natal
Query!
Country [57]
0
0
South Africa
Query!
State/province [57]
0
0
Mpumalanga
Query!
Country [58]
0
0
South Africa
Query!
State/province [58]
0
0
Durban
Query!
Country [59]
0
0
South Africa
Query!
State/province [59]
0
0
Observatory, Cape Town
Query!
Country [60]
0
0
Spain
Query!
State/province [60]
0
0
Barcelona
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Bilbao
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Elche (Alicante)
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Ferrol ( A Coruña)
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Granada
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
La Coruña
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
La Laguna-Tenerife
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Madrid
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Murcia
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Palma de Mallorca
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Pama de Mallorca
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
San Sebastian de los Reyes
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Santa Cruz de Tenerife
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Santander
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
Birmingham
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Coventry
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Leeds
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
ViiV Healthcare
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Janssen Pharmaceuticals
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/Industry
Query!
Name [2]
0
0
GlaxoSmithKline
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if
human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is
virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will
remain suppressed after switching to a two-drug intramuscular (IM) long-acting (LA) regimen
of cabotegravir (CAB) and rilpivirine (RPV). In this study, the INI STR will be limited to
abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). FLAIR is a Phase 3, multi-phase, randomized,
open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1,
anti-retroviral therapy (ART)-naïve adult participants. This study is designed to demonstrate
the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg
regimen every 4 weeks (Q4W: monthly) compared to remaining on ABC/DTG/3TC over 48 weeks (4
weeks oral CAB + RPV, 44 weeks LA therapy). Participants who are HLA-B*5701 positive at
Screening may enroll into the study and receive DTG plus a non-abacavir containing dual
nucleoside reverse transcriptase inhibitor (NRTI) regimen. Eligible participants will enroll
into the Induction Phase of the study and receive ABC/DTG/3TC for 20 weeks (Week [-20] to Day
1). Participants who have an HIV 1 ribose nucleic acid (RNA) <50 copies per milliliter (c/mL)
at Week (-4) will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue
ABC/DTG/3TC or to discontinue ABC/DTG/3TC and begin oral therapy with CAB 30 mg + RPV 25 mg
once daily for approximately 4 Weeks, followed by monthly CAB LA + RPV LA injections from
visit Week 4b until study completion or withdrawal. Participants who successfully complete
Week 100 (without meeting study defined withdrawal criteria and who remain virologically
suppressed through Week 96: HIV-1 RNA <50 c/mL) will be given the option to switch to the LA
arm in the Extension Phase (using an optional oral lead-in with CAB + RPV) or be withdrawn
from the study. Participants will continue to receive injections every 4 weeks during the
Extension Phase until CAB LA and RPV LA are either locally approved and commercially
available, the participant no longer derives clinical benefit, the participant meets a
protocol-defined reason for discontinuation, or until development of either CAB LA or RPV LA
is terminated.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02938520
Query!
Trial related presentations / publications
Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D'Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4.
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
ViiV Healthcare
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02938520
Download to PDF